NF-κb expression, clinical course and inflammatory response
after BAY-11-7082 prevented and treated
NF-κb level of spinal cord was detected in NF-κb blocker prevention and
treatment group and EAE control group by western blot. As the Figure 4a
shows, phosphorylated NF-κb level were lower in the EAE prevented and
treated group than in the EAE control group(EAE vs. prevent:
P<0.05).
We conducted experiments according to the grouping and administration
methods introduced in the previous method. As shown in Figure 4b, the
prevention group had a later disease onset than the EAE control
group(P<0.001), with a lower symptom
incidence(P<0.0001) and a lower score at the peak
hour(P<0.0001). The treatment group had concurrent onset with
EAE group; however, the score at peak hour was lower than EAE
group(P<0.001).
After treated by the NF-κb blocker, the spinal inflammatory cell
infiltrations were more severe in the EAE control groups than in the
prevention and treatment groups(P<0.0001). LFB staining showed
that spinal demyelination in the prevention and treatment groups was
significantly less severe than that in the EAE control
group(P<0.0001)(Figure 4c).
The pro-inflammatory cytokines, TNF-a, IL-6, IL-12p70 andIL-17A, were
lower in the NF-κb blocker (prevent and treated) group than in the
control group(P<0.05). Anti-inflammatory cytokines, IL-4 and
IL-10 are higher in NF-κb prevent group(P<0.001), but no
differences in treatment group(Figure 5a).